Dyadic International Inc. (NASDAQ:DYAI – Get Free Report) was the recipient of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 83,236 shares, a decline of 57.3% from the October 15th total of 194,728 shares. Based on an average daily trading volume, of 83,778 shares, the short-interest ratio is presently 1.0 days. Approximately 0.3% of the company’s shares are sold short.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Dyadic International stock. BlackRock Inc. bought a new stake in Dyadic International Inc. (NASDAQ:DYAI – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 197,749 shares of the biotechnology company’s stock, valued at approximately $177,000. BlackRock Inc. owned 0.54% of Dyadic International as of its most recent SEC filing. Hedge funds and other institutional investors own 27.95% of the company’s stock.
Dyadic International Stock Up 0.6%
Shares of DYAI traded up $0.00 during trading hours on Monday, reaching $0.33. 71,089 shares of the company traded hands, compared to its average volume of 171,096. The company’s fifty day moving average price is $0.42 and its two-hundred day moving average price is $0.74. The company has a market capitalization of $13.18 million, a price-to-earnings ratio of -1.57 and a beta of 1.10. Dyadic International has a 12 month low of $0.30 and a 12 month high of $1.60.
Dyadic International (NASDAQ:DYAI – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 226.85%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $1.43 million. On average, analysts expect that Dyadic International will post -0.15 EPS for the current year.
Analyst Ratings Changes
Separately, Weiss Ratings lowered Dyadic International from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has an average rating of “Sell”.
View Our Latest Analysis on DYAI
Dyadic International Company Profile
Dyadic International is a biotechnology company developing microbial expression systems to produce proteins for human and animal health applications. Its platforms are designed to help partners develop and manufacture biologics, including vaccines, therapeutics and diagnostic products. The company’s technologies include its C1 fungal expression system, based on a non-pathogenic microorganism, and its Dapibus yeast platform. Dyadic licenses these systems and related expertise to collaborators and also pursues development of selected products for health applications.
Further Reading
- Five stocks we like better than Dyadic International
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
